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Myoclonus‐dystonia (M‐D) is a rare hyperkinetic movement disorder characterized by upper body--predominant myoclonus and dystonia.[1](#mds28033-bib-0001){ref-type="ref"} A large proportion of cases are caused by autosomal‐dominant inherited mutations in the *SGCE* gene. In addition to the motor manifestations, psychiatric disorders are frequently reported.[2](#mds28033-bib-0002){ref-type="ref"} Several studies have suggested that they may form a primary component of the M‐D phenotype.[3](#mds28033-bib-0003){ref-type="ref"}, [4](#mds28033-bib-0004){ref-type="ref"} This study represents the first long‐term follow‐up study of both motor and psychiatric symptomatology in adults with M‐D (*SGCE* mutation), providing further insights into the natural history of M‐D and enabling more prognostic information.

Methods {#mds28033-sec-0002}
=======

Manifesting adult carriers with a mutation in the *SGCE* gene were included, whose baseline data were collected in the Netherlands, Belgium, and the United Kingdom and reported previously.[2](#mds28033-bib-0002){ref-type="ref"}, [3](#mds28033-bib-0003){ref-type="ref"}, [5](#mds28033-bib-0005){ref-type="ref"}

Regarding motor signs, both at baseline and follow‐up, Burk Fahn Marsden Dystonia Rating Scale (BFMDRS) and Unified Myoclonus Rating scale (UMRS) were used to objectively assess motor sign severity. Psychiatric comorbidity and quality of life were evaluated using the same (or highly comparable) questionnaires at baseline and follow‐up.

Results {#mds28033-sec-0003}
=======

Of the 63 adult M‐D patients recruited in the original studies, 27 patients were able to participate in this follow‐up assessment. An overview of body distribution and severity scales of motor signs at baseline and follow‐up examination can be found in Table [1](#mds28033-tbl-0001){ref-type="table"}. No age‐distinctive pattern in the scores was observed. See Table [1](#mds28033-tbl-0001){ref-type="table"} for the prevalence of psychiatric disorders and scores of severity scales. No associations between changes in motor symptoms and psychiatric symptom severity, quality of life, and demographic information were found.

###### 

Demographics, motor symptoms, and psychiatric comorbidities

  Total number of patients             27
  ------------------------------------ -----------
  Sex M/F                              11/16
  Age at onset dystonia (range)        8 (1--40)
  Age at onset myoclonus (range)       7 (1--17)
  Oral medication for motor symptoms   6 (22%)
  Antidepressant                       
  SSRI                                 4 (13%)
  SNRI                                 2 (7%)
  TCA                                  1 (3%)
  Botulinum neurotoxin injections      3 (11%)

  Motor symptoms                                       Baseline examination   Follow‐up examination   *P*
  ---------------------------------------------------- ---------------------- ----------------------- ------------------------------------------------------
  Age (SD)                                             44.6 (14.3)            55.2 (14.4)             
  Number of patients with:                                                                            
  Dystonia                                             23 (85%)               25 (93%)                0.625[a](#mds28033-note-0006){ref-type="fn"}
  Myoclonus                                            22 (81%)               24 (89%)                0.500[a](#mds28033-note-0006){ref-type="fn"}
  Body distribution                                                                                   
  Dystonia (n = 21)                                                                                   
  --- Upper limbs                                      5 (24%)                18 (86%)                **\< 0.001** [a](#mds28033-note-0006){ref-type="fn"}
  --- Lower limbs                                      2 (10%)                5 (24%)                 0.250[a](#mds28033-note-0006){ref-type="fn"}
  --- Neck                                             18 (86%)               19 (90%)                1.000[a](#mds28033-note-0006){ref-type="fn"}
  --- Trunk                                            5 (24%)                8 (38%)                 0.453[a](#mds28033-note-0006){ref-type="fn"}
  Myoclonus (n = 22)                                                                                  
  --- Upper limbs                                      20 (91%)               20 (91%)                1.000[a](#mds28033-note-0006){ref-type="fn"}
  --- Lower limbs                                      1 (5%)                 7 (32%)                 0.070[a](#mds28033-note-0006){ref-type="fn"}
  --- Neck                                             8 (36%)                16 (73%)                **0.008** [a](#mds28033-note-0006){ref-type="fn"}
  --- Trunk                                            6 (27%)                15 (68%)                **0.012** [a](#mds28033-note-0006){ref-type="fn"}
  All patients                                                                                        
  BFMDRS, n = 24 (range)                               3.5 (0--20)            6.6 (0--17.5)           0.203^b^
  UMRS, n = 24 (range)                                 2.3 (0--12)            3.7 (0--12)             0.140[b](#mds28033-note-0007){ref-type="fn"}
  Patients with mutation inherited via paternal line                                                  
  BFMDRS, n = 19 (range)                               4.0 (0--20)            7.0 (1--17.5)           0.198[b](#mds28033-note-0007){ref-type="fn"}
  UMRS, n = 19, (range)                                5.2 (0--12)            5.4 (0--12)             0.260[b](#mds28033-note-0007){ref-type="fn"}

                             Baseline examination   Follow‐up examination   
  -------------------------- ---------------------- ----------------------- -----------
  Any psychiatric disorder   16 (62%)               20 (77%)                0.219
  Depression                 7 (27%)                13 (50%)                0.070
  Panic disorder             6 (23%)                12 (46%)                **0.031**
  Social phobia              6 (23%)                4 (15%)                 0.688
  OCD                        3 (12%)                6 (23%)                 0.453
  Alcohol dependence         3 (12%)                3 (12%)                 1.000
  GAD                        3 (12%)                3 (12%)                 1.000
  Specific phobia            3 (14%)^3^             5 (23%)^3^              0.688
  Agoraphobia                4 (33%)^4^             6 (50%)^4^              0.500
  Hypomania                  1 (10%)^6^             1 (10%)^6^              1.000
  Psychosis                  1 (10%)^6^             2 (20%)^6^              1.000

                  n = 22        n = 22        *P* [b](#mds28033-note-0007){ref-type="fn"}
  --------------- ------------- ------------- ---------------------------------------------
  YBOCS (range)   0.0 (0--14)   0.0 (0--12)   0.634
  BDI (range)     5.0 (0--21)   7.5 (0--30)   **0.038**
  BAI (range)     5.0 (0--24)   7.5 (0--45)   0.070

                n = 13        n = 13       *P* [c](#mds28033-note-0008){ref-type="fn"}
  ------------- ------------- ------------ ---------------------------------------------
  QoL PC (SD)   44.8 (8.8)    45.2 (6.9)   0.875
  QoL MC (SD)   38.8 (13.6)   43.0 (9.2)   0.193

The following statistical tests were used:

McNemar test.

Wilcoxon signed rank test.

Paired‐sample *t* test: [1](#mds28033-bib-0001){ref-type="ref"}n = 9; ^2^n = 5; ^3^n = 22; ^4^n = 12; ^5^n = 7; ^6^n = 10.

SSRI, selective serotonin reuptake inhibitor; SNRI, selective serotonin and noradrenalin reuptake inhibitor; TCA, tricyclic antidepressant; BFMDRS, Burke Fahn Marsden Dystonia Rating Scale; UMRS, Unified Myoclonus Rating Scale; OCD, obsessive compulsive disorder; GAD, generalized anxiety disorder; YBOCS, Yale Brown Obsessive Compulsive Scale; BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; QoL PC, physical component of quality of life; QoL MC, mental component of quality of life.

Discussion {#mds28033-sec-0004}
==========

This is the first systematic long‐term follow‐up study of both motor and psychiatric manifestations in adult M‐D patients. Despite the percentage of patients retested (27 of 63), the rarity of M‐D makes our results valuable. Results of this study showed that in adulthood the course of dystonia and myoclonus is static and the prevalence of psychiatric comorbidities remains high. Specific psychiatric disorders, notably panic disorder and depression, became even more prevalent over time.

It appears that in adulthood severity of motor manifestations is relatively stable, but distribution lightly changed. At follow‐up examination significantly more patients had dystonia in the upper limbs and more patients had myoclonus in the neck and trunk compared with baseline. This is consistent with previous findings.[6](#mds28033-bib-0006){ref-type="ref"}

Comparable to the literature, psychiatric comorbidity was highly prevalent in our cohort. The prevalence of panic disorder doubled at follow‐up compared with baseline and was accompanied by an increased score on the anxiety severity scale. Similar, but not statistically significant, findings were detected for depressive disorder. It is unlikely that our findings are because of an increase in age, as the prevalence of panic disorder and depression in the general population tends to decrease in the age group of our cohort.[7](#mds28033-bib-0007){ref-type="ref"}

The relatively stable course of motor manifestations is in contrast with the increased prevalence of psychiatric comorbidity. Results highlight the need for more awareness and adequate treatment for psychiatric disorders in M‐D patients. Simultaneously, adult patients can be reassured that their motor functioning will not deteriorate.
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